1 Day CERO 5.49% DJIA 1.07% Russell 2K 1.53% Health Care/Life Sciences -1.43% ...

(RTTNews) - CERo Therapeutics Holdings, Inc. (CERO), a biotech company focused on next-generation engineered T cell immunotherapies using phagocytic mechanisms, has announced a securities purchase ...

SOUTH SAN FRANSCISCO, Calif, April 24, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (CERO), (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance ...

D. Boral Capital initiated coverage of Cero Therapeutics (CERO) with a Buy rating and $11 price target The company’s proprietary platform, designed to endow T cells with both innate and adaptive ...

CERo Therapeutics Holdings, Inc. has announced a securities purchase agreement to raise up to $8 million through a convertible preferred stock offering. The initial $5 million is expected from an ...

CERo Therapeutics Holdings, Inc. SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...